What Happened?
San Diego, -based Ansun-Biopharm Promoted Mikael Havluciyan as Chief Legal Officer and Corporate Secretary
About the Company
Ansun Biopharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses. Ansun Biopharma has two products in late stage clinical development. Fludase is a first-in-class broad-spectrum investigational therapeutic agent to treat all forms of influenza, including pandemic variants and drug-resistant variants that cannot be treated by any currently approved flu therapies, including H1N1, H5N1 and H7N9. Paradase is an investigational nebulized drug which is designed to target the receptor for parainfluenza viruses and is being evaluated in a Phase 2 trial for the treatment of lower tract parainfluenza infection in immunocompromised patients.
About the Person
Mikael Havluciyan is Chief Legal Officer and Corporate Secretary at Ansun Biopharm. Previously, Mikael held various senior legal leadership roles in the industry.
Info Source
News
Short Profile